Skip to reading
Read the study details alongside every finding.
Nuu Peptide

MOTS-c and NAD+ placed in context. Nobody here sells either.

ReferencesCompare
Menu

NAD+ and MOTS-c sources

The studies and official documents cited here, with a short account of what each contributes.

Reading this list

An original experiment, a review, and a regulatory document each have a different role. Original papers describe a particular method and result. Reviews place several findings together. FDA material addresses approval, safety concerns, or compounding, rather than demonstrating a treatment benefit.

Every source linked in the guide appears below. The notes identify the setting so that a human tissue study cannot quietly become a patient trial, or a precursor result become an infusion claim. The comparison shows how those distinctions affect a side-by-side reading.

Vinten and colleagues, 2025

This Nature Metabolism review examines human NAD+ precursor trials and the challenges of interpreting them. It describes limited clinical efficacy, incomplete evidence for age-related NAD+ decline in people, and sparse tissue-specific information. It supports the guide's caution about moving from blood changes to broad health claims.

Read the human precursor review. DOI: 10.1038/s42255-025-01387-7.

Yi and colleagues, 2023

This controlled NMN trial in middle-aged adults measured blood NAD+, walking distance, and quality-of-life outcomes over 60 days. It provides a human intervention example. The findings concern oral NMN in the enrolled population, with its particular follow-up period; they do not establish an NAD+ infusion effect.

Read the NMN intervention report. DOI: 10.1007/s11357-022-00705-1.

Yoshino and colleagues, 2021

This Science paper reports a ten-week NMN study in prediabetic, postmenopausal women. Muscle insulin sensitivity improved, while body composition and HbA1c did not. The guide uses it to explain why an accurate account needs to include unchanged outcomes beside the favorable measurement.

Read the muscle insulin-sensitivity study. DOI: 10.1126/science.abe9985.

Covarrubias and colleagues, 2021

This review explains NAD+ metabolism and its roles in cellular processes during aging. It covers electron transfer, NAD+-consuming enzymes, and routes that replenish the molecule. It provides chemical context for the guide rather than a clinical demonstration that raising NAD+ prevents disease.

Read the NAD+ metabolism review. DOI: 10.1038/s41580-020-00313-x.

Conze and colleagues, 2019

This controlled study examined oral nicotinamide riboside in healthy overweight adults over eight weeks. It measured increased whole-blood NAD+ and reported short-term tolerability. The guide keeps the preparation and population attached to the result, especially when explaining why it cannot answer infusion safety questions.

Read the NR trial. DOI: 10.1038/s41598-019-46120-z.

Koay and colleagues, 2025

This cardiac research combines human heart tissue with a mouse model of heart failure with preserved ejection fraction. It examines ketone production and the enzyme HMGCS2. The reported rescue of cardiac function occurred in mice, which limits the clinical conclusion that can be drawn.

Read the cardiac metabolism experiment. DOI: 10.1161/CIRCRESAHA.124.325550.

Kumagai and colleagues, 2024

This iScience paper investigates CK2 as a direct functional target of MOTS-c. It includes cell-free work and mouse experiments, with different effects in muscle and fat. The guide cites it for mechanistic detail and preserves the experimental setting rather than describing a human performance benefit.

Read the CK2 experiments. DOI: 10.1016/j.isci.2024.111212.

Bolignano and colleagues, 2024

This observational study followed 94 people receiving chronic hemodialysis and examined circulating MOTS-c in relation to mortality and cardiovascular events. It is a human biomarker study, not a treatment trial. Its patient group also limits how freely its associations can be generalized to healthy adults.

Read the hemodialysis cohort report. DOI: 10.1159/000540303.

Wan and colleagues, 2023

This review brings together MOTS-c research on metabolism, stress responses, and aging. It supplies context for the peptide's mitochondrial origin and the pathways described on the compound page. Much of the underlying evidence comes from cells and animals; a broad review does not change that evidence level.

Read the MOTS-c research overview. DOI: 10.1186/s12967-023-03885-2.

Reynolds and colleagues, 2021

This paper links exercise with endogenous MOTS-c expression in people and reports physical-performance experiments using administered peptide in mice. The guide distinguishes those parts of the work. The mouse performance findings cannot establish that giving MOTS-c to a person reproduces the benefits of exercise.

Read the exercise and muscle study. DOI: 10.1038/s41467-020-20790-0.

Kim and colleagues, 2018

This cell study examines movement of MOTS-c into the nucleus during metabolic stress and changes in gene regulation. It helps explain the signaling discussion. Its results concern cellular processes under experimental conditions, without establishing symptom improvement, safety, or a treatment outcome in humans.

Read the cellular stress experiments. DOI: 10.1016/j.cmet.2018.06.008.

FDA safety and compounding material

FDA's safety page, current as of April 22, 2026, places MOTS-c in the withdrawn-nominations table and retains its safety concerns. The date describes the page's currency, not a published date for an individual substance's withdrawal.

Read the FDA safety entries.

HHS's draft policy published October 30, 2026 says it does not intend to take enforcement action against state-licensed pharmacies and physicians compounding single-ingredient MOTS-c for an individual patient's prescription under set conditions. This nonbinding proposal is not FDA approval; MOTS-c remains off FDA's 503A bulks list. Blends and 503B outsourcing facilities are outside its scope.

The agency's written MOTS-c assessment for the July 2026 advisory meeting describes the gaps in human treatment and safety evidence. A staff assessment is distinct from a final approval decision.

Read the FDA MOTS-c assessment.

FDA's consumer explanation of compounded-drug risks describes the absence of premarket approval and the concerns that follow when a preparation is made improperly.

Read the compounded-drug risk explanation.

World Anti-Doping Agency, 2026

The international prohibited list names MOTS-c in its metabolic-modulator section. The restriction applies in and out of competition. This document supports the sport caution on the MOTS-c page; it is a competition rule source rather than a clinical study of benefits or side effects.

Read the 2026 prohibited list.